These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36757584)

  • 1. A review on curcumin colon-targeted oral drug delivery systems for the treatment of inflammatory bowel disease.
    Sardou HS; Vosough PR; Abbaspour M; Akhgari A; Sathyapalan T; Sahebkar A
    Inflammopharmacology; 2023 Jun; 31(3):1095-1105. PubMed ID: 36757584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook.
    Karthikeyan A; Young KN; Moniruzzaman M; Beyene AM; Do K; Kalaiselvi S; Min T
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33918207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin has bright prospects for the treatment of inflammatory bowel disease.
    Hanai H; Sugimoto K
    Curr Pharm Des; 2009; 15(18):2087-94. PubMed ID: 19519446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations.
    Baliga MS; Joseph N; Venkataranganna MV; Saxena A; Ponemone V; Fayad R
    Food Funct; 2012 Nov; 3(11):1109-17. PubMed ID: 22833299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease.
    Epstein J; Docena G; MacDonald TT; Sanderson IR
    Br J Nutr; 2010 Mar; 103(6):824-32. PubMed ID: 19878610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease.
    Meng ZW; Chang B; Sang LX
    World J Gastroenterol; 2024 Jan; 30(3):280-282. PubMed ID: 38314128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Curcumin a Possibility to Treat Inflammatory Bowel Diseases?
    Mazieiro R; Frizon RR; Barbalho SM; Goulart RA
    J Med Food; 2018 Nov; 21(11):1077-1085. PubMed ID: 29957091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers.
    Kabir MT; Rahman MH; Akter R; Behl T; Kaushik D; Mittal V; Pandey P; Akhtar MF; Saleem A; Albadrani GM; Kamel M; Khalifa SAM; El-Seedi HR; Abdel-Daim MM
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33800000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair.
    Lei F; Zeng F; Yu X; Deng Y; Zhang Z; Xu M; Ding N; Tian J; Li C
    J Nanobiotechnology; 2023 Aug; 21(1):275. PubMed ID: 37596598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin and inflammatory bowel disease: potential and limits of innovative treatments.
    Vecchi Brumatti L; Marcuzzi A; Tricarico PM; Zanin V; Girardelli M; Bianco AM
    Molecules; 2014 Dec; 19(12):21127-53. PubMed ID: 25521115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of therapeutic potentials of turmeric (Curcuma longa) and its active constituent, curcumin, on inflammatory disorders, pain, and their related patents.
    Razavi BM; Ghasemzadeh Rahbardar M; Hosseinzadeh H
    Phytother Res; 2021 Dec; 35(12):6489-6513. PubMed ID: 34312922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
    Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
    Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
    Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
    Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease.
    Qiao H; Fang D; Chen J; Sun Y; Kang C; Di L; Li J; Chen Z; Chen J; Gao Y
    Drug Deliv; 2017 Nov; 24(1):233-242. PubMed ID: 28156160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel disease.
    McCann MJ; Johnston S; Reilly K; Men X; Burgess EJ; Perry NB; Roy NC
    Nutrients; 2014 Oct; 6(10):4178-90. PubMed ID: 25314644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease.
    Gowd V; Kanika ; Jori C; Chaudhary AA; Rudayni HA; Rashid S; Khan R
    J Nutr Biochem; 2022 Nov; 109():109101. PubMed ID: 35777588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis.
    Ukil A; Maity S; Karmakar S; Datta N; Vedasiromoni JR; Das PK
    Br J Pharmacol; 2003 May; 139(2):209-18. PubMed ID: 12770926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review.
    Vafaeipour Z; Razavi BM; Hosseinzadeh H
    J Integr Med; 2022 May; 20(3):193-203. PubMed ID: 35292209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis and Turmeric as Complementary Treatments for IBD and Other Digestive Diseases.
    Quezada SM; Cross RK
    Curr Gastroenterol Rep; 2019 Jan; 21(2):2. PubMed ID: 30635796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colon-targeted oral nanoparticles based on ROS-scavenging hydroxyethyl starch-curcumin conjugates for efficient inflammatory bowel disease therapy.
    Xu C; Chen S; Chen C; Ming Y; Du J; Mu J; Luo F; Huang D; Wang N; Lin Z; Weng Z
    Int J Pharm; 2022 Jul; 623():121884. PubMed ID: 35661797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.